Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor

Cell. 1983 Dec;35(3 Pt 2):603-10. doi: 10.1016/0092-8674(83)90092-2.


We show that c-myc is an inducible gene that is regulated by specific growth signals in a cell-cycle-dependent manner. Specifically, agents that initiate the first phase of a proliferative response in lymphocytes (lipopolysaccharide or Concanavalin A) and fibroblasts (platelet-derived growth factor) induce c-myc mRNA. Within one to three hr after the addition of these mitogens to the appropriate cells, c-myc mRNA concentration is increased between 10- and 40-fold. This induction of c-myc mRNA occurs in the presence of cycloheximide and, therefore, does not require the synthesis of new protein species. Consequently, the induction of c-myc mRNA is not secondary to growth. In addition, c-myc mRNA is "superinduced" by the combination of cycloheximide and mitogen, a finding consistent with a model that a labile protein may regulate c-myc levels in these cells. Further, this work suggests a regulatory linkage between the function of two oncogenes--c-myc and c-sis--the latter being the putative structural gene for PDGF.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • B-Lymphocytes / physiology
  • Cell Cycle
  • Cells, Cultured
  • Cycloheximide / pharmacology
  • Gene Expression Regulation / drug effects*
  • Lymphocyte Activation / drug effects
  • Mice
  • Mitogens / pharmacology*
  • Oncogenes*
  • Platelet-Derived Growth Factor / pharmacology*
  • RNA, Messenger / genetics
  • T-Lymphocytes / physiology


  • Mitogens
  • Platelet-Derived Growth Factor
  • RNA, Messenger
  • Cycloheximide